Price Disclosure Reductions for 2018 October Cycle

This summary only includes medicines taking a price disclosure reduction on 1 October 2018. The determined price disclosure outcomes for this cycle were calculated in accordance with the National Health Act 1953 (the Act) as amended and National Health (Pharmaceutical Benefits) Regulations 2017 (the Regulations) in force currently.

The outcomes below show percentage (%) price differences and ex-manufacturer level prices. They do not include fees and mark-ups. Information about publication of prices including fees and mark-ups is set out below.

Flow-on Reductions for F2 Combination Items

Responsible persons with a brand of an F2 combination item should note that:

  • if an F2 combination item is listed below, it has met the criteria for a direct reduction. However, this reduction may not take effect on 1 October 2018 if the price of a component ingredient is also reduced and flowing this component price on results in a lower price; or
  • if an F2 combination item did not receive a direct price disclosure reduction, it may still receive a price reduction as a result of the flow-on of the price of a component ingredient that is taking a price disclosure reduction.

Calculations are currently being completed for flow-on price disclosure reductions to F2 combination items. Outcomes will be communicated to responsible persons with brands of affected drugs early July 2018.

Legal Determination & Next Steps

The weighted average disclosed prices for each brand, including brands with a determination but no reduction, can be found in the legal determination on the Federal Register of Legislation website. Price disclosure reductions will apply to brands listed in Schedule 1 of the legal determination. Those brands in Schedule 2 of the determination will not take a price disclosure reduction because the percentage difference between their April 2018 PBS approved ex-manufacturer price and the weighted average disclosed price was below 10% or 30% (as applicable and set out in the table below). Any new brands of an existing pharmaceutical item with a determination in Schedule 1 that listed after 31 March 2018 will also take the reduction on 1 October 2018 under section 99ADHA of the Act.

An agreed process for responsible persons to raise any questions or concerns arising from an outcome mentioned above is set out in the Price Disclosure Dispute Resolution Administrative Process. The date for lodgement of disputes is 5 pm AEST on 28 June 2018.

Indicative prices for 1 October 2018 (including price to pharmacy, dispensed price for maximum quantity and price premiums) will be published by early July 2018. Subscribe to PBS News to receive notice when they become available.

Final prices for 1 October 2018 (including all price to pharmacy, dispensed price for maximum quantity/amount and price premiums) will be available from mid-September 2018.

2018 October Cycle Outcomes Summary
Legal Instrument Drug
(drugs marked with an * have a pharmaceutical item/s that met the 'no reduction' criteria)		 Legal Instrument MoA Legal Instrument Form Average
AEMP
($)		 WAPD
(%)
across a
drug/MoA		 WADP -
potential
October '18
PBS Price (AEMP)
($)
per
pharmaceutical
item		 April '18
AEMP
($)		 Percentage difference between April '18 and October '18  PBS prices (AEMP)
(%)
per
pharmaceutical
item		 Calculations based on:

OWAPD = all brand data

GWAPD = originator brand data removed for at least one pharmaceutical item

No originator brand determined

Does not meet 30 month clock		 Unadjusted Price Reduction
10%
or
30%
 
[Average AEMP minus WAPD = WADP]   [Difference between October '18 AEMP & WADP = % Difference]
Adefovir Oral Tablet containing adefovir dipivoxil 10 mg 525.00 18.43% 428.24 525.00 18.43% GWAPD 10
Azacitidine Injection Powder for injection 100 mg 369.44 26.91% 270.02 317.31 14.90% Does not meet 30 month clock 10
Bleomycin Injection Powder for injection containing bleomycin sulfate 15,000 I.U. 31.27 31.78% 21.33 31.27 31.79% No originator brand determined 30
Bosentan Oral Tablet 125 mg (as monohydrate) 2,295.43 33.06% 1,536.56 2,295.43 33.06% Does not meet 30 month clock 10
Bosentan Oral Tablet 62.5 mg (as monohydrate) 2,295.43 33.06% 1,536.56 2,295.43 33.06% Does not meet 30 month clock 10
Capecitabine Oral Tablet 150 mg 15.07 33.09% 10.08 12.57 19.81% GWAPD 10
Capecitabine Oral Tablet 500 mg 93.40 33.09% 62.49 77.94 19.82% GWAPD 10
Dorzolamide Application to the Eye Eye drops 20 mg (as hydrochloride) per mL, 5 mL 10.11 27.75% 7.30 10.11 27.79% GWAPD 10
Dorzolamide with timolol Application to the Eye Eye drops containing dorzolamide 20 mg (as hydrochloride) with timolol 5 mg (as maleate) per mL, 5 mL 12.08 18.45% 9.85 12.08 18.46% GWAPD 10
Entecavir Oral Tablet 0.5 mg (as monohydrate) 306.68 31.26% 210.81 234.64 10.16% Does not meet 30 month clock 10
Entecavir Oral Tablet 1 mg (as monohydrate) 498.75 31.26% 342.84 381.59 10.15% Does not meet 30 month clock 10
Eplerenone Oral Tablet 25 mg 71.75 11.09% 63.79 71.75 11.09% Does not meet 30 month clock 10
Eplerenone Oral Tablet 50 mg 71.75 11.09% 63.79 71.75 11.09% Does not meet 30 month clock 10
Frusemide Injection Injection 20 mg in 2 mL 2.00 38.74% 1.23 2.00 38.50% OWAPD 30
Imatinib Oral Capsule 100 mg (as mesilate) 1,168.50 27.15% 851.25 1,168.50 27.15% Does not meet 30 month clock 10
Imatinib Oral Capsule 400 mg (as mesilate) 2,337.00 27.15% 1,702.50 2,337.00 27.15% Does not meet 30 month clock 10
Imatinib Oral Tablet 100 mg (as mesilate) 1,168.50 27.15% 851.25 1,168.50 27.15% Does not meet 30 month clock 10
Imatinib Oral Tablet 400 mg (as mesilate) 2,337.00 27.15% 1,702.50 2,337.00 27.15% Does not meet 30 month clock 10
Infliximab Injection Powder for I.V. infusion 100 mg 507.42 11.59% 448.61 507.42 11.59% Does not meet 30 month clock 10
Modafinil Oral Tablet 100 mg 126.00 13.53% 108.95 126.00 13.53% Does not meet 30 month clock 10
Nevirapine Oral Tablet 200 mg 157.14 34.88% 102.33 157.14 34.88% GWAPD 30
Nevirapine Oral Tablet 400 mg (extended release) 157.14 34.88% 102.33 157.14 34.88% GWAPD 30
Nicorandil Oral Tablets 10 mg, 60 13.00 26.82% 9.51 13.00 26.85% GWAPD 10
Nicorandil Oral Tablets 20 mg, 60 18.11 26.82% 13.25 18.11 26.84% GWAPD 10
Oxycodone* Oral Tablet containing oxycodone hydrochloride 10 mg (controlled release) 12.21 16.21% 10.23 12.21 16.22% GWAPD 10
Oxycodone* Oral Tablet containing oxycodone hydrochloride 20 mg (controlled release) 21.63 16.21% 18.12 21.63 16.23% GWAPD 10
Oxycodone* Oral Tablet containing oxycodone hydrochloride 40 mg (controlled release) 37.98 16.21% 31.82 37.98 16.22% GWAPD 10
Oxycodone* Oral Tablet containing oxycodone hydrochloride 5 mg 2.16 16.21% 1.81 2.16 16.20% GWAPD 10
Oxycodone* Oral Tablet containing oxycodone hydrochloride 80 mg (controlled release) 62.21 16.21% 52.13 62.21 16.20% GWAPD 10
Pemetrexed Injection Powder for I.V. infusion 1 g (as disodium) 208.08 55.58% 92.43 131.35 29.63% Does not meet 30 month clock 10
Pemetrexed Injection Powder for I.V. infusion 100 mg (as disodium) 20.81 55.58% 9.24 13.14 29.68% Does not meet 30 month clock 10
Pemetrexed Injection Powder for I.V. infusion 500 mg (as disodium) 104.04 55.58% 46.21 65.67 29.63% Does not meet 30 month clock 10
Pregabalin Oral Capsule 150 mg 41.96 25.00% 31.47 40.82 22.91% Does not meet 30 month clock 10
Pregabalin Oral Capsule 25 mg 12.36 25.00% 9.27 12.03 22.94% Does not meet 30 month clock 10
Pregabalin Oral Capsule 300 mg 62.60 25.00% 46.95 60.91 22.92% Does not meet 30 month clock 10
Pregabalin Oral Capsule 75 mg 27.35 25.00% 20.51 26.61 22.92% Does not meet 30 month clock 10
Raloxifene Oral Tablet containing raloxifene hydrochloride 60 mg 31.40 12.91% 27.35 31.40 12.90% GWAPD 10
Tirofiban Injection Solution concentrate for I.V. infusion 12.5 mg (as hydrochloride) in 50 mL 203.27 10.22% 182.50 203.27 10.22% GWAPD 10
Tranexamic acid Oral Tablet 500 mg 30.25 10.27% 27.14 30.25 10.28% Does not meet 30 month clock 10
Ursodeoxycholic acid* Oral Capsule 250 mg 136.00 28.58% 97.13 136.00 28.58% GWAPD 10
Valganciclovir Oral Tablet 450 mg (as hydrochloride) 1,792.15 15.95% 1,506.30 1,792.15 15.95% Does not meet 30 month clock 10
Valsartan with hydrochlorothiazide Oral Tablet 160 mg-12.5 mg 12.04 28.55% 8.60 9.95 13.57% GWAPD 10
Valsartan with hydrochlorothiazide Oral Tablet 160 mg-25 mg 13.45 28.55% 9.61 11.36 15.40% GWAPD 10
Valsartan with hydrochlorothiazide Oral Tablet 320 mg-12.5 mg 15.04 28.55% 10.75 12.36 13.03% GWAPD 10
Valsartan with hydrochlorothiazide Oral Tablet 320 mg-25 mg 16.45 28.55% 11.75 13.77 14.67% GWAPD 10
Valsartan with hydrochlorothiazide Oral Tablet 80 mg-12.5 mg 9.69 28.55% 6.92 8.06 14.14% GWAPD 10

Confirmed prices of brands scheduled for a price disclosure reduction

The Confirmed Prices Report outlines the approved ex-manufacturer prices for brands scheduled to take a price disclosure reduction. The reports for the 2018 October cycle can be downloaded below.

Last updated
27 September 2018